The Prostaglandin E2 Pathway and Breast Cancer Stem Cells: Evidence of Increased Signaling and Potential Targeting

Culprits of cancer development, metastasis, and drug resistance, cancer stem cells (CSCs) are characterized by specific markers, active developmental signaling pathways, metabolic plasticity, increased motility, invasiveness, and epithelial-mesenchymal transition. In breast cancer, these cells are often more prominent in aggressive disease, are amplified in drug-resistant tumors, and contribute to recurrence. For breast cancer, two distinct CSC populations exist and are typically defined by CD44+/CD24- cell surface marker expression or increased aldehyde dehydrogenase (ALDH) activity. These CSC populations share many of the same properties but also exhibit signaling pathways that are more active in CD44+/CD24- or ALDH+ populations. Understanding these CSC populations and their shared or specific signaling pathways may lead to the development of novel therapeutic strategies that will improve breast cancer patient outcomes. Herein, we review the current evidence and assess published patient tumor datasets of sorted breast CSC populations for evidence of heightened prostaglandin E2 (PGE(2)) signaling and activity in these breast CSC populations. PGE(2) is a biologically active lipid mediator and in cancer PGE(2) promotes tumor progression and poor patient prognosis. Overall, the data suggests that PGE(2) signaling is important in propagating breast CSCs by enhancing inherent tumor-initiating capacities. Development of anti-PGE(2) signaling therapeutics may be beneficial in inhibiting tumor growth and limiting breast CSC populations.

Automated summary

Cancer stem cells (CSCs) play a crucial role in cancer development, metastasis, and drug resistance. In breast cancer, there are two distinct CSC populations with similar properties but different signaling pathways. Understanding these CSC populations and their signaling pathways may lead to the development of novel therapeutic strategies for improving breast cancer patient outcomes.